一种大环类双核非离子型磁共振对比剂的合成及弛豫性能
收稿日期: 2021-02-05
修回日期: 2021-03-12
网络出版日期: 2021-04-12
基金资助
江苏省自然科学基金(BK20181486); 江苏省高校自然科学基金(17KJB320001); 江苏省高校优秀中青年教师和校长境外研修计划和江苏省青蓝工程资助项目.
Synthesis and Relaxivity of One Macrocyclic Binuclear Nonionic Magnetic Resonance Contrast Agent
Received date: 2021-02-05
Revised date: 2021-03-12
Online published: 2021-04-12
Supported by
Natural Science Foundation of Jiangsu Province(BK20181486); Natural Science Foundation of the Jiangsu Higher Education Institutions(17KJB320001); Overseas Training Program for Excellent Young Teachers and Principals of Jiangsu Province and the Qing Lan Project of Jiangsu Province.
磁共振成像技术被广泛应用于诊断医学和软组织成像, 而磁共振对比剂有助于提高成像对比度. 报道了一种基于钆-DOTA-酰肼结构(DOTA=1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸)的新型双核非离子型磁共振对比剂(Gd-DOTAH)2-SBDC的设计、合成及弛豫性能. 在0.5 T磁场下, 测得其纵向弛豫率为每分子10.6 L•mmol–1•s–1或5.3 L•mmol–1•Gd–1•s–1, 高于目前临床使用的单核大环对比剂钆- DOTA. 体外磁共振成像研究显示该磁共振对比剂具有提高诊断灵敏度和准确度的特点. 同时, 该对比剂分子中含有能与髓鞘特异性结合的二苯乙烯结构, 具有成为髓鞘靶向磁共振对比剂的应用潜力. 另外, 探讨了该对比剂的两条合成路线(A和B), 总收率分别为70%和75%. 综合考虑适用性, 合成路线B更优.
周进 , 孙宏顺 , 李玉龙 , 蒋蕻 , 郭成 , 沈临江 . 一种大环类双核非离子型磁共振对比剂的合成及弛豫性能[J]. 有机化学, 2021 , 41(7) : 2767 -2773 . DOI: 10.6023/cjoc202102009
Magnetic resonance imaging (MRI) is widely employed in diagnostic medicine and soft tissue imaging. Contrast agents (CAs) can improve the specificity of enhanced MRI images. Herein, the design, synthesis and relaxivity of a novel binuclear nonionic Gd-based DOTA-hydrazide (DOTA=1,4,7,10-tetraazacyclododecan-1,4,7,10-tetraacetic acid) derived MRI contrast agents, (Gd-DOTAH)2-SBDC, were reported. The improved longitudinal relaxivity was determined as 10.6 L•mmol–1•s–1 per molecule or 5.3 L•mmol–1•Gd–1•s–1at 0.5 T, which is higher than that of the mononuclear clinical macrocyclic agent Gd-DOTA.In vitro MRI studies confirmed its suitability for use as a MRI contrast agent with improved diagnostic sensitivity and accuracy. Furthermore, the stilbene moiety endows it with myelin-targeting capabilities. In addition, two synthetic routes (A and B) for this contrast agent were compared, providing overall yields of 70% and 75%, respectivily, and route B was deemed superior.
Key words： magnetic resonance imaging; contrast agents; synthesis; relaxivity; DOTA-hydrazide; Gd-DOTA; myelin
| [1] | Wei, R.; Gong, X.; Lin, H.; Zhang, K.; Li, A.; Liu, K.; Shan, H.; Chen, X.; Gao, J. Nano Lett. 2019, 19,5394. |
| [2] | Mi, P.; Kokuryo, D.; Cabral, H.; Wu, H.; Terada, Y.; Saga, T.; Aoki, I.; Nishiyama, N.; Kataoka, K. Nat. Nanotechnol. 2016, 11,724. |
| [3] | Wahsner, J.; Gale,E. M.; Rodríguez-Rodríguez, A.; Caravan, P. Chem. Rev. 2019, 119,957. |
| [4] | Ide?e,J. -M.; Port, M.; Robic, C.; Medina, C.; Sabatou, M.; Corot, C. J. Magn. Reson. Imaging. 2009, 30,1249. |
| [5] | Di Gregorio, E.; Gianolio, E.; Stefania, R.; Barutello, G.; Digilio, G.; Aime, S. Anal. Chem. 2013, 85,5627. |
| [6] | Marckmann, P.; Skov, L.; Rossen, K.; Dupont, A.; Damholt,M. -B.; Heaf,J. -G.; Thomsen,H. -S. J. Am. Soc. Nephrol. 2006, 17,2359. |
| [7] | Jost, G.; Lenhard,D. -C.; Sieber,M. -A.; Lohrke, J.; Frenzel, T.; Pietsch, H. Invest Radiol. 2016, 51,83. |
| [8] | Lauffer,R. -B. Chem. Rev. 1987, 87,901. |
| [9] | Caravan, P. Acc. Chem. Res. 2009, 42,851. |
| [10] | Hermann, P.; Kotek, J.; Kubicek, V.; Lukes, I. Dalton Trans. 2008, 23,3027. |
| [11] | Luo, J.; Li,W. -S.; Xu, P.; Zhang,L. -Y.; Chen,Z. -N. Inorg. Chem. 2012, 51,9508. |
| [12] | Zhao, G.; Lu, C.; Li, H.; Xiao, Y.; Zhang, W.; Fang, X.; Wang, P.; Fang, X.; Xu, J.; Yang, W. Inorg. Chim. Acta 2013, 406,146. |
| [13] | Zhao, G.; Li, H.; Lu, C.; Xiao, Y.; Fang, X.; Wang, P.; Fang, X.; Zhao, K.; Li, X.; Yin, S.; Xu, J.; Yang, W. RSC Adv. 2012, 2,6404. |
| [14] | Tiwari,A. -D.; Zhu, J.; You, J.; Eck, B.; Zhu, J.; Wang, X.; Wang, X.; Wang, B.; Silver, J.; Wilson, D.; Wu, C.; Wang, Y. J. Med. Chem. 2019, 62,4902. |
| [15] | Frullano, L.; Zhu, J.; Miller,R. -H.; Wang, Y. J. Med. Chem. 2013, 56,1629. |
| [16] | Frullano, L.; Zhu, J.; Wang, C.; Wu, C.; Miller,R. -H.; Wang, Y. J. Med. Chem. 2012, 55,94. |
| [17] | Sun,H. -S.; Li,Y. -L.; Jiang, H.; Guo, C.; Shen,L. -J. Chin. J. Org. Chem. 2018, 38,1779 (in Chinese). |
| [17] | ( 孙宏顺, 李玉龙, 蒋蕻, 郭成, 沈临江, 有机化学, 2018, 38,1779.) |
| [18] | Sun,H. -S.; Zhou, J.; Li,Y. -L.; Jiang, H.; Zhang, Y.; Wang, J.; Guo, C.; Shen,L. -J. Chin. J. Org. Chem. 2019, 39,778 (in Chinese). |
| [18] | ( 孙宏顺, 周进, 李玉龙, 蒋蕻, 张艳, 王建强, 郭成, 沈临江, 有机化学, 2019, 39,778.) |
| [19] | Sun,H. -S.; Li,Y. -L.; Jiang, H.; Xu, N.; Lu, X.; Chen, Y. CN 1077595333, 2017.[Chem. Abstr. 2018, 168, 326713] |
| [20] | Wang, C.; Wu, C.; Popescu,D. -C.; Zhu, J.; Macklin,W. -B.; Miller,R. -H.; Wang, Y. J. Neurosci. 2011, 31,2382. |
| [21] | Wang, C.; Wu, C.; Zhu, J.; Miller,R. -H.; Wang, Y. J. Med. Chem. 2011, 54,2331. |
| [22] | Frullano, L.; Wang, C.; Miller,R. -H.; Wang, Y. J. Am. Chem. Soc. 2011, 133,1611. |
| [23] | Tiwari,A. -D.; Wu, C.; Zhu, J.; Zhang, S.; Zhu, J.; Wang,W. -R.; Zhang, J.; Tatsuoka, C.; Matthews,P. -M.; Miller,R. -H.; Wang, Y. J. Med. Chem. 2016, 59,3705. |
| [24] | Wu, C.; Eck, B.; Zhang, S.; Zhu, J.; Tiwari,A. -D.; Zhang, Y.; Zhu, Y.; Zhang, J.; Wang, B.; Wang, X.; Wang, X.; You, J.; Wang, J.; Guan, Y.; Liu, X.; Yu, X.; Trapp,B. -D.; Miller, R.; Silver, J.; Wilson, D.; Wang, Y. J. Med. Chem. 2017, 60,987. |
| [25] | Zhou, J.; Yang,H. -D.; Sun,H. -S.; Li,Y. -L.; Jiang, H. Chin. J. Synth. Chem. 2017, 25,159 (in Chinese). |
| [25] | ( 周进, 杨海东, 孙宏顺, 李玉龙, 蒋蕻, 合成化学. 2017, 25,159.) |
| [26] | Aime, S.; Caravan, P. J. Magn. Reson. Imaging. 2009, 30,1259. |
| [27] | Frullano, L.; Tejerina, B.; Meade,T. J. Inorg. Chem. 2006, 45,8489. |
| [28] | Saini, N.; Varshney, R.; Tiwari,A. K.; Kaul, A.; Allard, M.; Ishar,M. P.S.; Mishra,A. K. Dalton Trans. 2013, 42,4994. |
| [29] | Gao, L.; Yu, J.; Liu, Y.; Zhou, J.; Sun, L.; Wang, J.; Zhu, J.; Peng, H.; Lu, W.; Yu, L.; Yan, Z.; Wang, Y. Theranostics 2018, 8,92. |
/
| 〈 |
|
〉 |
